Trial · NCT05570305
Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
NCT05570305, Phase 2, Completed, University Medical Center Groningen
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria. Trials, record NCT05570305. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05570305
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria
- NCT number
- NCT05570305
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 42 participants, actual
- Lead sponsor
- University Medical Center Groningen
- Conditions
- Chronic Kidney Diseases
- Interventions
- Zibotentan, Dapagliflozin, Placebo, Dapagliflozin and Zibotentan
- First posted
- 2022-10-06
- Last updated
- 2025-04-30
- Other registries' IDs
- eudract:2021-001324-18
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in albuminuria after 4 weeks combined zibotentan and dapagliflozin treatment versus four weeks treatment with zibotentan alone. | The albuminuria will be measured before start of medication intake and after the last intake of medication for each treatment period. This concerns a 4 week time frame. | The change in albuminuria as expressed the percentage change of the log-transformed albumin:creatinine ratio in mg/gram. The log-transformation is because of the skewed distribution. |
| Secondary | Change in Extracellular Fluid | 4 weeks | Extracellular Fluid measured by bioimpedance spectroscopy |
| Secondary | Change in bodyweight | 4 weeks | Change in kilograms |
| Secondary | Change in NT-proBNP | 4 weeks | N-terminal B-type natriuretic peptide (NT-proBNP) |
| Secondary | Change in BNP | 4 weeks | B-type natriuretic peptide (BNP) |
| Secondary | Change in Glomerular Filtration Rate (GFR) | 4 weeks | Glomerular Filtration Rate (GFR) using iohexol clearance techniques. |
| Secondary | Change in Extracellular volume (ECV) | 4 weeks | Extracellular volume (ECV) using iohexol clearance techniques. |
| Secondary | Change in hematocrit | 4 weeks | The percentage of red blood cells in blood |
| Secondary | Change in systolic and diastolic blood pressure | 4 weeks | Change in blood pressure as measure in mmHg |
| Other | Change in renin-angiotensin-aldosterone system (RAAS) markers | 4 weeks | Change in RAAS markers in plasma and urine |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 41805697 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05570305
GET https://conductscience.org/api/trials/v1/NCT05570305/registered